Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of QX002N in active ankylosing spondylitis
ChiCTR2100053338Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of crusekitug in ankylosing spondylitis (AS), sponsored by Peking Union Medical College Hospital. Primary endpoint: Proportion of subjects achieving ASAS20. Started Dec 2021; status: recruiting.
02
Drugs
crusekitug
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR2100053338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053338.